特一药业：2025年前三季度公司实现营业总收入6.92亿元

Core Insights - The company has reported significant growth in revenue and net profit for the first three quarters of 2025, with total revenue reaching 692 million yuan, a year-on-year increase of 51.86% [1] - The net profit attributable to shareholders was 65.22 million yuan, reflecting a remarkable year-on-year growth of 985.18% [1] - Sales of the core product, "Te Yi" cough tablets, have steadily recovered, achieving 64% of the sales volume compared to the same period in 2023 [1] - The company has made positive progress in expanding its online business [1] - The operational performance for 2025 is in line with the company's internal planning expectations [1] - The finance department is currently conducting annual financial accounting in an orderly manner [1] - The company will fulfill its information disclosure obligations in a timely manner based on the financial accounting results [1]